Sellas Life Sciences Group, Inc. · NASDAQ:SLS
Sellas Life Sciences — Galena Biopharma — Merger or Acquisition (December 2017)
11 slides from Sellas Life Sciences's merger presentation, Dec 8, 2017
Slide 1: Proposed Merger Summary
PROPOSED MERGER SUMMARY December 8, 2017
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT Some of the information contained in this presentation may include forward-looking statements about strategy, future operations, future financial position, prospects, plans and objectives of management of Galena Biopharma, Inc. (“Galena”), SELLAS Life Sciences Group Ltd (“S
Slide 3: Proposed Merger Details
PROPOSED MERGER DETAILS Special Meeting of Stockholders: December 15, 2017 Time: 9:00 a.m. Eastern Standard Time Location: Paul Hastings LLP, 200 Park Avenue, New York, NY All materials available on the SEC and the Galena websites: Galena CEO Letter to Stockholders Proxy statement/prospectus/consent
Slide 4: Why Vote for the Merger
WHY VOTE FOR THE MERGER Synergistic clinical development programs create a cancer immunotherapy pipeline with multiple oncology targets Galinpepimut-S (GPS) is targeting Wilm’s Tumor 1 (WT1) which is ranked as a leading antigen by the National Cancer Institute Multiple GPS clinical trials ongoing an
Slide 5: Proposal Summary
PROPOSAL SUMMARY Proposals 1, 2 and 3 must be approved by stockholders for the Merger to occur If approved, Proposal 4 would provide the continuing company with the ability to raise necessary equity capital in the future, within certain parameters, without obtaining further stockholder approval Prop
Slide 6: Continuing Company Pipeline
CONTINUING COMPANY PIPELINE PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 SELLAS ASSET: Galinpepimut-S (GPS) Acute Myeloid Leukemia Phase 3 Planned (pending funding availability) Mesothelioma Phase 3 Planned (pending funding availability) Multiple Myeloma – Single Arm Ovarian Cancer (combo with nivolu
Slide 7: Recent Announcements
RECENT ANNOUNCEMENTS SELLAS presents GPS data from the ongoing Phase 2 trial in multiple myeloma patients at the Annual Meeting of the Society of Hematologic Oncology (SOHO) SELLAS entered into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA Initiati
Slide 8: Continuing Company Leadership Team
CONTINUING COMPANY LEADERSHIP TEAM Name POSITION PRIOR EXPERIENCE Angelos M. Stergiou, M.D., Sc.D. h.c. Chief Executive Officer Paion AG, Biovest International, Accentia, Analytica, Avanex Life Sciences Nicholas J. Sarlis, M.D., Ph.D., FACP Chief Medical Officer NIH, MD Anderson, Sanofi, Incyte Alek
Slide 9: hs Wasranhas been reser merntonl Gene Cause and Corprate eeu f ean Tepes, rR
\ Ls hs Wasranhas been reser merntonl Gene Cause and Corprate eeu f ean Tepes, rR a pub Wades Bopheaceste Company ne abr 202, marapng fe nerstona eg Cast, and Cmglancencton, Fam ar 201 url cober 201 he wa ears Cit State Develo, cent Cour an oforat Setar an om May 208 tl nay 2012 he was eran’ Ect Vie
Slide 10: Continuing Company Board of Directors
CONTINUING COMPANY BOARD OF DIRECTORS Robert L. Van Nostrand Mr. Van Nostrand will be appointed to the continuing company’s board of directors effective as of the closing of the Merger. Mr. Van Nostrand is currently on the Board of Directors of Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), a biote
Slide 11: Vote Your Shares Today
VOTE YOUR SHARES TODAY Call (212) 929-5500 (Collect) Call (800) 322-2885 (toll free in North America)
Galena Biopharma — Merger or Acquisition (December 2017) on 6ix